| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Mirikizumab (anti-IL-23)
CAS:1884201-71-1
Purity:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human I Package:100μg Remarks:K13679
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Mirikizumab
CAS:1884201-71-1
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Mirikizumab
CAS:1884201-71-1
Purity:95% Package:1mg;1g;100g
|
|
| | Mirikizumab Basic information |
| Product Name: | Mirikizumab | | Synonyms: | Mirikizumab;Research Grade Mirikizumab(DHJ63105);Research Grade Mirikizumab;Mirikizumab (anti-IL-23) | | CAS: | 1884201-71-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Mirikizumab Structure]() |
| | Mirikizumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Mirikizumab Usage And Synthesis |
| Uses | Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease[1][2]. | | in vivo | Mirikizumab (7.5 mg/kg, i.p., administered at 9, 16, and 32 hours) exhibits anti-inflammatory activity in an acute systemic mouse model[2]. | Animal Model: | Acute systemic C57BL/6 mice model | | Dosage: | 7.5 mg/kg | | Administration: | Intraperitoneal injection (i.p.), dosing time of 9, 16, 32 h | | Result: | Inhibited human IL-23-induced mouse IL-17A, IL-17F, and keratin-16 mRNA production in an acute systemic mice model. |
| | References | [1] Jefremow A, et al. Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical Perspective. Immunotargets Ther. 2020 Nov 26;9:289-297.
[2] Steere B, et al. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23. J Pharmacol Exp Ther. 2023 Nov;387(2):180-187. Steere B, Beidler C, Martin A, Bright S, Kikly K, Benschop RJ. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23. J Pharmacol Exp Ther. 2023 Nov;387(2):180-187. DOI:10.1124/jpet.122.001512 |
| | Mirikizumab Preparation Products And Raw materials |
|